GRTS Stock Summary and Trading Ideas (Gritstone Bio | NASDAQ:GRTS)

Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.

Gritstone Bio trades on the NASDAQ stock market under the symbol GRTS.

As of April 19, 2024, GRTS stock price declined to $0.74 with 1,484,085 million shares trading.

GRTS has a beta of 2.69, meaning it tends to be more sensitive to market movements. GRTS has a correlation of 0.05 to the broad based SPY ETF.

GRTS has a market cap of $78.37 million. This is considered a Micro Cap stock.

Last quarter Gritstone Bio reported $10 million in Revenue and -$.26 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.08.

In the last 3 years, GRTS stock traded as high as $14.42 and as low as $.67.

The top ETF exchange traded funds that GRTS belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IWN.

GRTS has underperformed the market in the last year with a price return of -72.0% while the SPY ETF gained +21.2%. GRTS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -73.1% and -28.8%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

GRTS support price is $.69 and resistance is $.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRTS stock will trade within this expected range on the day.